TS23 / Translational Sciences - LARVOL DELTA

STRATEGY FOR IMPROVING STROKE TREATMENT RESPONSE (SISTER): A PHASE-2 CLINICAL TRIAL OF TS23, A NOVEL MECHANISM FOR IMPROVING OUTCOMES IN ACUTE ISCHEMIC STROKE (ESOC 2025) - P2 | "SISTER will test the safety and preliminary efficacy of TS23 among patients with AIS within 4.5-24 hours of LKW. If the trial is successful, pivotal testing of TS23 for AIS will be planned. Figure 1."

Clinical • P2 data • Cardiovascular • Ischemic stroke • Thrombosis

Strategy for Improving Stroke Treatment Response (SISTER): A Phase-2 Clinical Trial of TS23, a novel mechanism for improving outcomes in acute ischemic stroke (ISC 2025) - P2 | "Introduction: Plasminogen activators (Alteplase and Tenecteplase) for acute ischemic stroke (AIS), while effective, suffer from limitations and untoward effects. SISTER will rigorously test the safety and preliminary efficacy of TS23 among patients with AIS within 4.5-24 hours of last known well. If the trial is successful, pivotal testing of TS23 for AIS will be planned."

Clinical • P2 data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Thrombosis

SISTER: Strategy for Improving Stroke Treatment Response (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Translational Sciences, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Ischemic stroke

SISTER: Strategy for Improving Stroke Treatment Response (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: Translational Sciences, Inc.

Trial completion date • Trial initiation date • Trial primary completion date • Cardiovascular • Ischemic stroke

SISTER: Strategy for Improving Stroke Treatment Response (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: Translational Sciences, Inc.

New P2 trial • Cardiovascular • Ischemic stroke

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: Translational Sciences, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Pulmonary Embolism • Respiratory Diseases

"Heading to DC ✈️ to attend Translational Science 2023 #TS23xInnovate #TS23 @ACTScience #TopTen @CRForumUS" (@Ali_Aminian_MD)

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial (clinicaltrials.gov) - P2 | N=32 | Not yet recruiting | Sponsor: Translational Sciences, Inc.

New P2 trial • Cardiovascular • Pulmonary Embolism • Respiratory Diseases